Gemici, Ali IhsanSerin, İstemiErol, Vedat BuğraDoğu, Mehmet HilmiKarakuş, Volkan2022-12-302022-12-302022GEMİCİ A, SERİN İ, EROL V, DOĞU M, İNCE İ, EREN R, TEKİNALP A, KARAKUŞ V, SEVİNDİK Ö (2022). Quality of Life Assessment with EORTC QLQ in Patients with Hodgkin Lymphoma: Multicenter Study. ACTA ONCOLOGICA TURCICA, 55(2), 128 - 138. 10.5505/aot.2022.25991http://dx.doi.org/10.5505/aot.2022.25991https://hdl.handle.net/20.500.12713/3790Aim: The aim of our study is to obtain data on the quality of life (QoL) in Hodgkin lymphoma (HL) patients in a representative sample of the general population of Turkey with the help of the EORTC QLQ-C30 and QLQ-HL27 questionnaires. Material and Methods: A total of 68 patients from seven different centers diagnosed with HL between 2018-2020 were included in the study. The questionnaires were answered cross-sectionally by the patient under the control of a physician in the centers participating in the study. Results: Out of 68 patients, 42.6% (n=29) were female and 57.4% (n=39) were male. The ages of the patients ranged from 18 to 74 years, with a mean of 42.10±16.62 and with a median value of 40 years. There was no significant difference between age subgroups in terms of QLQ-C30 global health status/ QoL, functional or symptom scales and HL27 SB, PC, EI and WF scores (p>0.05, for all). It was determined that the constipation scores of females were higher than the scores of males (p=0.041). No statistically significant difference was found in terms of HL27 SB, PC, EI and WF sub-dimension scores according to gender (p>0.05). Conclusions: There was only a statistically significant difference in terms of QLQ-C30 constipation sub-dimension scores according to gender. The constipation scores of females were higher than the scores of men. More detailed and large population studies are needed to reveal the effectiveness of QoL assessment in HL patients.eninfo:eu-repo/semantics/openAccessHodgkin lymphomaEORTC QLQ-C30QLQ-HL27Quality Of LifeQuality of Life assessment with EORTC QLQ in patients with hodgkin lymphoma: multicenter studyArticle55212813810.5505/aot.2022.259911122840